<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560687</url>
  </required_header>
  <id_info>
    <org_study_id>2018-1</org_study_id>
    <nct_id>NCT03560687</nct_id>
  </id_info>
  <brief_title>CardioSideral Heart Surgery: Randomized Study on Sucrosomial Iron Supplementation Before Heart Surgery</brief_title>
  <acronym>CHS</acronym>
  <official_title>CardioSideral Heart Surgery: Randomized Study on Sucrosomial Iron Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiochirurgia E.H.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiochirurgia E.H.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, single blind (Outcomes Assessor), non-profit study is aimed at verifying
      whether routine preoperative supplementation with Sucrosomial® Iron in patients scheduled for
      cardiac surgery may increase baseline haemoglobin, constrain the haemoglobin decrease between
      postoperative day 2 and 3 (haemoglobin drift), and reduce the postoperative transfusion
      requirements, in order to identify a new strategy for pre-hospitalization optimization and
      post-operative recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, single blind (Outcomes Assessor), non-profit study is aimed at verifying
      whether routine preoperative supplementation with Sucrosomial® Iron in patients scheduled for
      cardiac surgery may increase baseline haemoglobin, constrain the haemoglobin decrease between
      postoperative day 2 and 3 (haemoglobin drift), and reduce the postoperative transfusion
      requirements, in order to identify a new strategy for pre-hospitalization optimization and
      post-operative recovery.

      Secondary Objectives are

        -  Changes in blood chemistry and biochemical tests between pre- and post-intervention

        -  Evaluation of tolerability and compliance of supplementation with Sucrosomal Iron

        -  Reduction in the number of transfusions and blood bags used

        -  Evaluation of cost-effectiveness
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Actual">July 9, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization of 1000 consecutive patients undergoing heart surgery to either Iron supplementation or Control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Single blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Preoperative Hemoglobin Level</measure>
    <time_frame>30 days from enrollment</time_frame>
    <description>Preoperative Hemoglobin Level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance to drug</measure>
    <time_frame>30 days from enerollemnt</time_frame>
    <description>Discontinuation rate due to adverse effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness in terms of cost of drug vs saved blood units</measure>
    <time_frame>30 days after operation</time_frame>
    <description>Cost-effectiveness in terms of cost of drug vs saved blood units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Level 24 hours after operation</measure>
    <time_frame>24 hours after index operation</time_frame>
    <description>Hemoglobin Level 24 hours after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Level 48 hours after operation</measure>
    <time_frame>48 hours after index operation</time_frame>
    <description>Hemoglobin Level 48 hours after operation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1023</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>CardioSIDERAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adminsitration of 2 pills per day of CArdiosideral from 30 days before operation to time of operation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sucrosomial Iron</intervention_name>
    <description>CardioSideral 2 caps per day</description>
    <arm_group_label>CardioSIDERAL</arm_group_label>
    <other_name>CardioSideral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Undergoing elective Heart Surgery -

        Exclusion Criteria:

        - Emergent or Urgent Indication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Weltert</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiochirurgia European Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 7, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cardiochirurgia E.H.</investigator_affiliation>
    <investigator_full_name>Luca Weltert</investigator_full_name>
    <investigator_title>Clinical Professor, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Heart Surgery</keyword>
  <keyword>Iron Supplementation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

